This credit facility extends FDMT's cash runway significantly without equity dilution, a positive for a pre-revenue biotech. Watch for milestone-driven tranche draws (especially Tranche 2A/2B) as indicators of pipeline progress. The floating-rate structure means rising rates would increase interest costs, but the primary risk is execution on clinical milestones to unlock the full facility.
Price Chart
Executive Summary
4D Molecular Therapeutics entered into a $200M senior secured term loan facility with Hercules Capital, drawing an initial $20M on June 24, 2026. The facility provides significant non-dilutive capital to fund operations and pipeline development, with additional tranches tied to milestone achievements. The loan is secured by substantially all assets including IP, and carries floating interest rates starting at 8.75% for the initial tranche.
Key Financial Metrics
Key Facts
- Up to $200M senior secured term loan facility with Hercules Capital, Inc.
- $20M Tranche 1A drawn at closing on June 24, 2026
- Additional tranches: $30M (Tranche 1B, available until June 15, 2027), $12.5M (2A), $12.5M (2B), $50M (3), $25M (4), $50M (5) — most subject to milestone achievement or Hercules discretion
- Maturity date: June 1, 2031
- Tranche 1A interest rate: greater of prime + 2.00% or 8.75%; other tranches: greater of prime + 2.50% or 9.25%
- Initial facility charge of $500,000; tranche facility charge of 1.00% for Tranches 2-5
- Financial covenants include minimum cash requirements and a performance covenant tied to FDA approval and revenue milestones
- Loan is secured by substantially all assets, including intellectual property
Financial Impact
$20M drawn immediately, with potential access to up to $200M total; interest costs at 8.75%+ floating rate
Risk Factors
- Floating interest rate exposure — rising prime rate increases borrowing costs
- Milestone-dependent tranches may not be drawn if clinical/regulatory targets are missed
- Covenants include minimum cash and performance tests that could restrict financial flexibility
- Loan is secured by all assets including IP, creating downside risk in distress scenario
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-286880 |
| Document: 0001193125-26-286880-index-headers.html | 0001193125-26-286880 |
| Document: 0001193125-26-286880-index.html | 0001193125-26-286880 |
| Document: 0001193125-26-286880.txt | 0001193125-26-286880 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Insider Cluster | $15.00 $14.71 | ▲ +1.93% | ▲ +1.85% | $11.96 (+20.27%) |
Aug 21, 2026 9w ago | Insider Cluster | $15.39 $15.72 | ▲ +2.14% | ▲ +1.82% | $11.96 (−22.29%) |
Jul 20, 2026 14w ago | 8-K | $11.09 $11.38 | ▲ +2.57% | ▲ +1.74% | $11.96 (+7.84%) |
Jul 18, 2026 14w ago | Press Release | $11.09 $11.38 | ▲ +2.57% | ▲ +1.74% | $11.96 (+7.84%) |
Jul 5, 2026 16w ago | Institutional Cluster | $12.72 $12.82 | ▲ +0.79% | ▲ +1.26% | $11.96 (−5.97%) |
Jun 29, 2026 17w ago | 8-K | $12.88 $13.30 | ▲ +3.26% | ▲ +2.48% | $11.96 (−7.14%) |
May 14, 2026 23w ago | EFFECT | $9.81 $9.15 | ▼ −6.73% | ▼ −5.50% | $11.96 (+21.92%) |
May 7, 2026 24w ago | S-3 | $10.14 $10.79 | ▲ +6.41% | ▲ +6.18% | $11.96 (+17.95%) |
Mar 18, 2026 31w ago | Press Release | $8.98 $8.61 | ▼ −4.12% | ▼ −2.38% | $11.96 (+33.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers